Innovative Cellular Therapeutics Holdings Ltd - 06 Nov 2025 SCHEDULE 13G Report for Lyell Immunopharma, Inc. Common Stock, par value $0.0001 (LYEL)

Filing Manager
Innovative Cellular Therapeutics Holdings Ltd
Reporting Manager
Innovative Cellular Therapeutics Holdings Ltd
Security
Lyell Immunopharma, Inc. Common Stock, par value $0.0001
Symbol
LYEL
Shares outstanding
19,387,755 shares
Disclosed Ownership
1,900,000 shares
Ownership
9.8%
Form type
SCHEDULE 13G
Filing time
13 Nov 2025, 17:04:28 UTC
Date of event
06 Nov 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Innovative Cellular Therapeutics Holdings Ltd disclosed 9.8% ownership in Lyell Immunopharma, Inc. Common Stock, par value $0.0001 (LYEL) on 06 Nov 2025."

Quick Takeaways

  • Innovative Cellular Therapeutics Holdings Ltd filed SCHEDULE 13G for Lyell Immunopharma, Inc. Common Stock, par value $0.0001 (LYEL).
  • Disclosed ownership: 9.8%.
  • Date of event: 06 Nov 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 13 Nov 2025, 17:04.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (1)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Innovative Cellular Therapeutics Holdings Ltd 9.8% 1,900,000 1,900,000 0 /s/ Lei Xiao Lei Xiao/ Chief Executive Officer

Sponsored